GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BB Biotech AG (GREY:BBAGF) » Definitions » Return-on-Tangible-Asset

BB Biotech AG (BB Biotech AG) Return-on-Tangible-Asset : 17.25% (As of Dec. 2023)


View and export this data going back to . Start your Free Trial

What is BB Biotech AG Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. BB Biotech AG's annualized Net Income for the quarter that ended in Dec. 2023 was $504.70 Mil. BB Biotech AG's average total tangible assets for the quarter that ended in Dec. 2023 was $2,925.75 Mil. Therefore, BB Biotech AG's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2023 was 17.25%.

The historical rank and industry rank for BB Biotech AG's Return-on-Tangible-Asset or its related term are showing as below:

BBAGF' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -21.77   Med: 4.88   Max: 51.19
Current: -7.72

During the past 13 years, BB Biotech AG's highest Return-on-Tangible-Asset was 51.19%. The lowest was -21.77%. And the median was 4.88%.

BBAGF's Return-on-Tangible-Asset is ranked better than
76.91% of 1555 companies
in the Biotechnology industry
Industry Median: -39.47 vs BBAGF: -7.72

BB Biotech AG Return-on-Tangible-Asset Historical Data

The historical data trend for BB Biotech AG's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BB Biotech AG Return-on-Tangible-Asset Chart

BB Biotech AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 20.49 19.26 -10.44 -10.62 -7.55

BB Biotech AG Quarterly Data
Jun16 Sep16 Dec16 Mar17 Jun17 Dec17 Dec18 Dec19 Dec20 Mar21 Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.61 -36.08 -2.11 -7.60 17.25

Competitive Comparison of BB Biotech AG's Return-on-Tangible-Asset

For the Biotechnology subindustry, BB Biotech AG's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BB Biotech AG's Return-on-Tangible-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BB Biotech AG's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where BB Biotech AG's Return-on-Tangible-Asset falls into.



BB Biotech AG Return-on-Tangible-Asset Calculation

BB Biotech AG's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-238.907/( (3277.575+3049.438)/ 2 )
=-238.907/3163.5065
=-7.55 %

BB Biotech AG's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=504.7/( (2802.069+3049.438)/ 2 )
=504.7/2925.7535
=17.25 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Dec. 2023) net income data.


BB Biotech AG  (GREY:BBAGF) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


BB Biotech AG Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of BB Biotech AG's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


BB Biotech AG (BB Biotech AG) Business Description

Traded in Other Exchanges
Address
Schwertstrasse 6, Schaffhausen, CHE, CH-8200
BB Biotech AG is a part of the healthcare sector in Switzerland. Its primary activity includes making investments, especially in the biotechnology market and is one of the largest investors in the field of biotechnology. The focus of the investments is on those listed companies that focus on the development and marketing of novel drugs with a clear value for the healthcare system. BB Biotech follows a strategy of carefully screening and selecting biotechnology firms with a long-term time horizon and having established products in the marketplace. Geographically it earns key revenue from the Netherlands.

BB Biotech AG (BB Biotech AG) Headlines

No Headlines